



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



(±)-Atenolol-d₇ Item No. 30018

CAS Registry No.: 1202864-50-3
Formal Name: 4-[2-hydroxy-3-[[1-(methyl-d₃)ethyl-1,2,2,2-d₄]amino]propoxy]-benzeneacetamide
Synonyms: (R,S)-Atenolol-d₇, Duraatenol, ICI 66082
MF: C₁₄D₇H₁₅N₂O₃
FW: 273.4
Chemical Purity: ≥95% (Atenolol)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₇); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

(±)-Atenolol-d₇ is intended for use as an internal standard for the quantification of (±)-atenolol (Item No. 17250) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

(±)-Atenolol-d₇ is supplied as a solid. A stock solution may be made by dissolving the (±)-atenolol-d₇ in the solvent of choice, which should be purged with an inert gas. (±)-Atenolol-d₇ is slightly soluble in chloroform and methanol.

Description

(±)-Atenolol is an antagonist of the β₁-adrenergic receptor (β₁-AR; K_i = 1.14 μM).¹ It is selective for β₁-ARs over β₂-ARs (K_i = 48.7 μM). (±)-Atenolol (200 mg/kg per day) delays the onset of hypertension in spontaneously hypertensive rats.² Formulations containing atenolol have been used in the treatment of high blood pressure.

References

1. Golf, S., Bjornerheim, R., Erichsen, A., *et al.* Relative selectivity of different β-adrenoceptor antagonists for human heart β₁- and β₂-receptor subtypes assayed by a radioligand binding technique. *Scand. J. Clin. Lab. Invest.* **47(7)**, 719-723 (1987).
2. Richer, C., Boissier, J.R., and Giudicelli, J.F. Chronic atenolol treatment and hypertension development in spontaneously hypertensive rats. *Eur. J. Pharmacol.* **47(4)**, 393-400 (1978).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/06/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM